ESCMID Global 2026: Zelicapavir demonstrates benefits for high-risk adults with RSV
Enanta is in a strong position to dominate the largely untapped RSV therapeutics market with a Phase III trial on the horizon.
Therapy Area
ESCMID Global 2026: Adibelivir emerges as potential disease-modifying therapy for HSV
Immunotherapy in locally advanced HNSCC: is there still room for new agents?
FDA issues complete response letter to Replimune’s RP1 for melanoma
ACC 2026: Meta-analysis supports CagriSema as superior first-line therapy in obesity
ACC 2026: dulaglutide promotes coronary plaque stabilisation in patients with T2D
Non-invasive diagnostics in endometriosis: at the cusp of a turning point
ACC 2026: Baxdrostat lowers BP in uncontrolled hypertension
